CHRNA9
Neuronal acetylcholine receptor subunit alpha-9
As of the edition of 20 October 2026, CHRNA9 (neuronal acetylcholine receptor subunit alpha-9, UniProt Q9UGM1) has 1 drug tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UGM1
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Nervous system; Ear, nose and throat; Eye; Immune system; Inherited and neonatal; Mental health
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Neramexane | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Merz Pharma GmbH & Co. KGaA | Route A |
| Actavis | Route A |
The other 0 companies at CHRNA9
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at CHRNA9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.